Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Equity Income (2019 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Equity Income for 7 consecutive years, with $678000.0 as the latest value for Q3 2025.

  • Quarterly Equity Income changed 0.0% to $678000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$1.0 million through Sep 2025, down 144.62% year-over-year, with the annual reading at -$1.1 million for FY2024, 380.86% down from the prior year.
  • Equity Income for Q3 2025 was $678000.0 at Ultragenyx Pharmaceutical, up from -$9000.0 in the prior quarter.
  • The five-year high for Equity Income was $25.7 million in Q3 2021, with the low at -$31.0 million in Q2 2021.
  • Average Equity Income over 5 years is -$3.2 million, with a median of -$334000.0 recorded in 2023.
  • Peak annual rise in Equity Income hit 1221.56% in 2024, while the deepest fall reached 1629.12% in 2024.
  • Over 5 years, Equity Income stood at -$16.1 million in 2021, then soared by 111.43% to $1.8 million in 2022, then grew by 2.66% to $1.9 million in 2023, then tumbled by 181.95% to -$1.5 million in 2024, then surged by 143.8% to $678000.0 in 2025.
  • According to Business Quant data, Equity Income over the past three periods came in at $678000.0, -$9000.0, and -$157000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.